Pub Date : 2017-12-23DOI: 10.1504/IJHTM.2017.10009747
Jenna Smith-Turchyn, Janelle Gravesande, G. Agarwal, D. Mangin, D. Javadi, J. Peter, F. Parascandalo, L. Dolovich, J. Richardson
Risk factor modification interventions using mobile health technology have been shown to be effective in managing non-communicable lifestyle related conditions. The objective of this study was to explore how older adults with type 2 diabetes and hypertension use an online app developed to help manage these conditions. Usability testing was conducted on the TAPESTRY-CM Healthy Lifestyle App, an online self-management application. This included an online session, using a cognitive interviewing approach, and semi-structured interviews at various times. Qualitative content analysis was performed as sessions were completed using coding and category formation. All participants commented positively on app content. Suggestions for improvement were given in regard to app content and layout. This study provides strong support for initial use of this app. Results of this study will be used to improve the app prior to conducting larger scale effectiveness trials or using it in clinical practice.
{"title":"A healthy lifestyle app for older adults with diabetes and hypertension: usability assessment","authors":"Jenna Smith-Turchyn, Janelle Gravesande, G. Agarwal, D. Mangin, D. Javadi, J. Peter, F. Parascandalo, L. Dolovich, J. Richardson","doi":"10.1504/IJHTM.2017.10009747","DOIUrl":"https://doi.org/10.1504/IJHTM.2017.10009747","url":null,"abstract":"Risk factor modification interventions using mobile health technology have been shown to be effective in managing non-communicable lifestyle related conditions. The objective of this study was to explore how older adults with type 2 diabetes and hypertension use an online app developed to help manage these conditions. Usability testing was conducted on the TAPESTRY-CM Healthy Lifestyle App, an online self-management application. This included an online session, using a cognitive interviewing approach, and semi-structured interviews at various times. Qualitative content analysis was performed as sessions were completed using coding and category formation. All participants commented positively on app content. Suggestions for improvement were given in regard to app content and layout. This study provides strong support for initial use of this app. Results of this study will be used to improve the app prior to conducting larger scale effectiveness trials or using it in clinical practice.","PeriodicalId":51933,"journal":{"name":"International Journal of Healthcare Technology and Management","volume":"16 1","pages":"250"},"PeriodicalIF":1.0,"publicationDate":"2017-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66972814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-12-23DOI: 10.1504/IJHTM.2017.10009750
Shreya M. Banerjee, A. Sarkar
In recent days, distinct healthcare information systems use and exchange electronic clinical documents enormously. Further, modern technologies, such as connected home monitoring devices, incorporate contextual awareness into clinical documents. Besides this, today's healthcare domain is driven by emergence of new roles played by related stakeholders. Consequently, there is a need in healthcare information systems to achieve common semantic interpretation of clinical documents so that, 1) those can be exchanged among healthcare information systems meaningfully; 2) personalised document view in a specific context can be achieved effectively. To address these issues in this paper, an ontology driven meta-model for clinical documents is proposed. The proposed conceptualisation is implemented in an ontology editorial tool Protege and illustrated using a case study based on e-prescription. Further, the specification is transformed towards JSON (Java Script Object Notation Schema) schema for demonstration of its practical utility.
{"title":"Ontology driven meta-modelling of clinical documents","authors":"Shreya M. Banerjee, A. Sarkar","doi":"10.1504/IJHTM.2017.10009750","DOIUrl":"https://doi.org/10.1504/IJHTM.2017.10009750","url":null,"abstract":"In recent days, distinct healthcare information systems use and exchange electronic clinical documents enormously. Further, modern technologies, such as connected home monitoring devices, incorporate contextual awareness into clinical documents. Besides this, today's healthcare domain is driven by emergence of new roles played by related stakeholders. Consequently, there is a need in healthcare information systems to achieve common semantic interpretation of clinical documents so that, 1) those can be exchanged among healthcare information systems meaningfully; 2) personalised document view in a specific context can be achieved effectively. To address these issues in this paper, an ontology driven meta-model for clinical documents is proposed. The proposed conceptualisation is implemented in an ontology editorial tool Protege and illustrated using a case study based on e-prescription. Further, the specification is transformed towards JSON (Java Script Object Notation Schema) schema for demonstration of its practical utility.","PeriodicalId":51933,"journal":{"name":"International Journal of Healthcare Technology and Management","volume":"16 1","pages":"271"},"PeriodicalIF":1.0,"publicationDate":"2017-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46559654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-10-24DOI: 10.1504/IJHTM.2017.10008507
Jie Zhang
Although mobile device healthcare (MDH) industry is developing fast, people do not have a deep understanding of its value chain, and further, its business model. In this paper, I analyse the development of The MDH industry in China, then clarify the total market scale of MDH. Based on these, I discuss key segments in the value chain of MDH industry and unveil the business model of MDH firms. After that, the change brought by the mobile devices for the traditional healthcare industry is investigated. Finally, six cases of MDH firms in China are raised and discussed in detail.
{"title":"Value chain building and business model in the mobile device healthcare industry - the case of China","authors":"Jie Zhang","doi":"10.1504/IJHTM.2017.10008507","DOIUrl":"https://doi.org/10.1504/IJHTM.2017.10008507","url":null,"abstract":"Although mobile device healthcare (MDH) industry is developing fast, people do not have a deep understanding of its value chain, and further, its business model. In this paper, I analyse the development of The MDH industry in China, then clarify the total market scale of MDH. Based on these, I discuss key segments in the value chain of MDH industry and unveil the business model of MDH firms. After that, the change brought by the mobile devices for the traditional healthcare industry is investigated. Finally, six cases of MDH firms in China are raised and discussed in detail.","PeriodicalId":51933,"journal":{"name":"International Journal of Healthcare Technology and Management","volume":"16 1","pages":"59"},"PeriodicalIF":1.0,"publicationDate":"2017-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44336958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-10-24DOI: 10.1504/IJHTM.2017.10006645
Pamela Lattanzi, Federica Monti, Zhao Xu
It is unanimously recognised in the literature that although the Chinese pharmaceutical market offers huge opportunities to European industry, it poses several challenges regarding compliance with the laws governing this sector. Because of the different legal traditions, a peculiar public health history and culture, and a different system of healthcare, EU companies have faced many barriers in accessing the Chinese pharmaceutical market over the years. In order to provide a better understanding of the China's regulatory landscape and its emerging trends, the article focuses on three critical legal topics, which are relevant for the business of EU pharmaceutical companies in the Chinese market: drug registration, drug distribution system, and IP rights protection.
{"title":"China's legal framework for pharmaceutical products: challenges and opportunities for EU companies","authors":"Pamela Lattanzi, Federica Monti, Zhao Xu","doi":"10.1504/IJHTM.2017.10006645","DOIUrl":"https://doi.org/10.1504/IJHTM.2017.10006645","url":null,"abstract":"It is unanimously recognised in the literature that although the Chinese pharmaceutical market offers huge opportunities to European industry, it poses several challenges regarding compliance with the laws governing this sector. Because of the different legal traditions, a peculiar public health history and culture, and a different system of healthcare, EU companies have faced many barriers in accessing the Chinese pharmaceutical market over the years. In order to provide a better understanding of the China's regulatory landscape and its emerging trends, the article focuses on three critical legal topics, which are relevant for the business of EU pharmaceutical companies in the Chinese market: drug registration, drug distribution system, and IP rights protection.","PeriodicalId":51933,"journal":{"name":"International Journal of Healthcare Technology and Management","volume":"16 1","pages":"128-154"},"PeriodicalIF":1.0,"publicationDate":"2017-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42371425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-10-24DOI: 10.1504/IJHTM.2017.087596
Manli Huang, Huiru Zhang, Antonio Angelino
This article assesses the influence of sub-national marketisation on the equity share choice in mergers and acquisitions. Focusing on domestic acquisitions, we examine the relationship between marketisation of the target firm and the acquirer firm's equity share choice by Guangdong (GD) firms in pharmaceuticals. Our sample consists of 53 domestic acquisitions in China of which acquirers are located in GD province and targets are located all over China. Findings confirm that differences exist in equity share choice based on different sub-national marketisation within China. Sub-national marketisation has significant association with equity share in cross-province acquisitions. An acquirer will more likely opt for partial shares in the acquired firm than full shares when acquiring a firm across provinces.
{"title":"Chinese pharmaceuticals: does sub-national marketisation matter? Evidence of cross-province acquisitions by Guangdong pharmaceutical firms","authors":"Manli Huang, Huiru Zhang, Antonio Angelino","doi":"10.1504/IJHTM.2017.087596","DOIUrl":"https://doi.org/10.1504/IJHTM.2017.087596","url":null,"abstract":"This article assesses the influence of sub-national marketisation on the equity share choice in mergers and acquisitions. Focusing on domestic acquisitions, we examine the relationship between marketisation of the target firm and the acquirer firm's equity share choice by Guangdong (GD) firms in pharmaceuticals. Our sample consists of 53 domestic acquisitions in China of which acquirers are located in GD province and targets are located all over China. Findings confirm that differences exist in equity share choice based on different sub-national marketisation within China. Sub-national marketisation has significant association with equity share in cross-province acquisitions. An acquirer will more likely opt for partial shares in the acquired firm than full shares when acquiring a firm across provinces.","PeriodicalId":51933,"journal":{"name":"International Journal of Healthcare Technology and Management","volume":"16 1","pages":"95"},"PeriodicalIF":1.0,"publicationDate":"2017-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1504/IJHTM.2017.087596","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41859081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-10-24DOI: 10.1504/IJHTM.2017.10006769
M. R. D. Tommaso, S. Bonnini, Y. Qi
TCM is a key part of the Chinese healthcare system and TCM industries might play a growing role in the domestic and international markets. This work focuses on TCM listed companies in China. In particular, we study the effect of ownership and size on corporate performance. Multivariate permutation tests on the effects of ownership and size on corporate performance show that among the TCM listed companies, private companies perform better than state-owned ones, while big companies perform better than small ones. Moreover, the study shows that in TCM industry ownership has stronger effects than size on corporate performance.
{"title":"Focusing on the Chinese health industry: an empirical enquiry on the TCM listed firms. Is large and private beautiful?","authors":"M. R. D. Tommaso, S. Bonnini, Y. Qi","doi":"10.1504/IJHTM.2017.10006769","DOIUrl":"https://doi.org/10.1504/IJHTM.2017.10006769","url":null,"abstract":"TCM is a key part of the Chinese healthcare system and TCM industries might play a growing role in the domestic and international markets. This work focuses on TCM listed companies in China. In particular, we study the effect of ownership and size on corporate performance. Multivariate permutation tests on the effects of ownership and size on corporate performance show that among the TCM listed companies, private companies perform better than state-owned ones, while big companies perform better than small ones. Moreover, the study shows that in TCM industry ownership has stronger effects than size on corporate performance.","PeriodicalId":51933,"journal":{"name":"International Journal of Healthcare Technology and Management","volume":"16 1","pages":"77"},"PeriodicalIF":1.0,"publicationDate":"2017-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47455377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-10-24DOI: 10.1504/IJHTM.2017.10008509
Yan Wei, R. Pong, Lizheng Shi, J. Ming, Meng Tang, Yiwei Mao, Wenbin Liu, Yingyao Chen
Although health technology assessment (HTA) has existed in China since the 1980s, the integration of HTA and policy-making is still in its infancy. Knowledge translation (KT) can play an important role in facilitating evidence-based policy-making. This study aims to describe the process of KT from researches to policy-makers and identifying the main determinants of the use of HTA evidence in policy-making in China. Researchers' and health policy-makers' perceptions of HTA KT were identified, using a grounded theory analysis approach. A theoretical framework consisting of four domains emerged to represent researchers' and policy-makers' perceptions of KT from HTA to policy making. Health policy-makers and researchers identified several determinants of KT, including HTA KT processes, alignment between research and decision-making and features of HTA research and health decisions, communication between policy-makers and HTA researchers, and support and resources for KT (organisational support, researchers' and health policy-makers' personal relationships and macro environment support).
{"title":"Perceptions of health technology assessment knowledge translation in China: a qualitative study on HTA researchers and policy-makers","authors":"Yan Wei, R. Pong, Lizheng Shi, J. Ming, Meng Tang, Yiwei Mao, Wenbin Liu, Yingyao Chen","doi":"10.1504/IJHTM.2017.10008509","DOIUrl":"https://doi.org/10.1504/IJHTM.2017.10008509","url":null,"abstract":"Although health technology assessment (HTA) has existed in China since the 1980s, the integration of HTA and policy-making is still in its infancy. Knowledge translation (KT) can play an important role in facilitating evidence-based policy-making. This study aims to describe the process of KT from researches to policy-makers and identifying the main determinants of the use of HTA evidence in policy-making in China. Researchers' and health policy-makers' perceptions of HTA KT were identified, using a grounded theory analysis approach. A theoretical framework consisting of four domains emerged to represent researchers' and policy-makers' perceptions of KT from HTA to policy making. Health policy-makers and researchers identified several determinants of KT, including HTA KT processes, alignment between research and decision-making and features of HTA research and health decisions, communication between policy-makers and HTA researchers, and support and resources for KT (organisational support, researchers' and health policy-makers' personal relationships and macro environment support).","PeriodicalId":51933,"journal":{"name":"International Journal of Healthcare Technology and Management","volume":"16 1","pages":"44"},"PeriodicalIF":1.0,"publicationDate":"2017-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49255246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.1504/IJHTM.2017.10006561
Manli Huang, Huiru Zhang, Antonio Angelino
{"title":"Chinese pharmaceuticals: does sub-national marketization matter? Evidence of cross-province acquisitions by Guangdong firms","authors":"Manli Huang, Huiru Zhang, Antonio Angelino","doi":"10.1504/IJHTM.2017.10006561","DOIUrl":"https://doi.org/10.1504/IJHTM.2017.10006561","url":null,"abstract":"","PeriodicalId":51933,"journal":{"name":"International Journal of Healthcare Technology and Management","volume":"124 1","pages":"1"},"PeriodicalIF":1.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66973064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.1504/IJHTM.2017.10008836
S. Barsanti, S. D. Rosis
{"title":"Multi-level determinants of tele-healthcare innovations: an Italian case study.","authors":"S. Barsanti, S. D. Rosis","doi":"10.1504/IJHTM.2017.10008836","DOIUrl":"https://doi.org/10.1504/IJHTM.2017.10008836","url":null,"abstract":"","PeriodicalId":51933,"journal":{"name":"International Journal of Healthcare Technology and Management","volume":"1 1","pages":"1"},"PeriodicalIF":1.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66972753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-08-17DOI: 10.1504/IJHTM.2016.078336
D. M. Cooper, M. Whitfield, D. Newton, J. Chiarella, K. Machaczek
Financial challenges that the National Health Service (NHS), England, faces may jeopardise its future. This study evaluated the direct cost of using two different safety peripheral intravenous cannulae (SPIVC) with and without a blood control septum, including the cost of device and clinician time. Observation of 103 cannulations demonstrated a 54 second (29%) time reduction per cannulation with the non-ported SPIVC with multi-use blood control septum (Introcan Safety® 3 B Braun), compared to the standard ported SPIVC (Vasofix® Safety B Braun) (P < 0.05). The direct cost analysis, including clinician time, demonstrated that the introduction of SPIVC with multi-use blood control septum could offer time efficiency savings equivalent to a reduction in average cannulation costs by 25%. 82% of users perceived the insertion of SPIVC with multi-use blood control septum to be easy to use; 82% would choose to use it in clinical practice.
英国国家医疗服务体系(NHS)面临的财政挑战可能会危及其未来。本研究评估了使用两种不同的安全外周静脉插管(SPIVC)的直接成本，包括设备成本和临床时间。103次插管的观察表明，与标准端口SPIVC (Vasofix®Safety B Braun)相比，使用多用途血液控制隔(Introcan Safety®3 B Braun)的非端口SPIVC每次插管时间减少54秒(29%)(P < 0.05)。包括临床医生时间在内的直接成本分析表明，引入SPIVC和多用途血液控制隔膜可以节省时间效率，相当于平均降低25%的插管成本。82%的用户认为SPIVC与多用途血液控制隔膜的插入易于使用;82%的人会选择在临床实践中使用它。
{"title":"Introduction of a non-ported peripheral intravenous catheter with multi-use blood control septum offers improvements in the overall efficiency of the procedure and is clinically well accepted","authors":"D. M. Cooper, M. Whitfield, D. Newton, J. Chiarella, K. Machaczek","doi":"10.1504/IJHTM.2016.078336","DOIUrl":"https://doi.org/10.1504/IJHTM.2016.078336","url":null,"abstract":"Financial challenges that the National Health Service (NHS), England, faces may jeopardise its future. This study evaluated the direct cost of using two different safety peripheral intravenous cannulae (SPIVC) with and without a blood control septum, including the cost of device and clinician time. Observation of 103 cannulations demonstrated a 54 second (29%) time reduction per cannulation with the non-ported SPIVC with multi-use blood control septum (Introcan Safety® 3 B Braun), compared to the standard ported SPIVC (Vasofix® Safety B Braun) (P < 0.05). The direct cost analysis, including clinician time, demonstrated that the introduction of SPIVC with multi-use blood control septum could offer time efficiency savings equivalent to a reduction in average cannulation costs by 25%. 82% of users perceived the insertion of SPIVC with multi-use blood control septum to be easy to use; 82% would choose to use it in clinical practice.","PeriodicalId":51933,"journal":{"name":"International Journal of Healthcare Technology and Management","volume":"15 1","pages":"177"},"PeriodicalIF":1.0,"publicationDate":"2016-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1504/IJHTM.2016.078336","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66971180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：